Sarcopenia in cancer: Risking more than muscle loss.
Sarcopenia in cancer: Risking more than muscle loss.
复制标题
DOI：
10.1016/j.tipsro.2020.10.001
复制
发表时间：
2020-12
影响因子：
--
通讯作者：
Choudhury A
中科院分区：
文献类型：
--
作者：
Anjanappa M;Corden M;Green A;Roberts D;Hoskin P;McWilliam A;Choudhury A
骨质疏松症的特征是进行性和广泛的骨骼肌退变，并与功能衰退有关。骨质疏松症有原发病和继发性病因，分别是由于衰老过程或慢性细胞因子介导的炎症(与包括癌症在内的健康状况有关)引起的。骨质疏松症的诊断依赖于检测到骨骼肌力量、质量和性能的降低。非放射学方法和放射学方法的结合可以用来评估每一种方法，进而准确诊断骨质疏松症。众所周知，骨质疏松症会对各种形式的癌症患者的预后产生不利影响。早期发现骨质疏松症是改善患者护理和整体预后的关键。各种干预措施，如抗阻运动、营养支持、氨基酸和维生素补充剂，在治疗石棺减少症方面显示出了希望。然而，为了更好地支持癌症患者，需要进一步深入了解新的干预措施，甚至评估治疗石棺减少症在生存方面的好处。
Sarcopenia is characterised by progressive and extensive skeletal muscle degeneration and is associated with functional decline. Sarcopenia has primary and secondary aetiology, arising as a result of the ageing process or through chronic cytokine-mediated inflammation (associated with health conditions including cancer), respectively. Diagnosis of sarcopenia is dependent upon detection of reduced skeletal muscle strength, mass and performance. A combination of non-radiological and radiological methods can be used to assess each of these in turn to accurately diagnose sarcopenia. Sarcopenia is known to adversely affect outcomes of patients with various forms of cancer. Early identification of sarcopenia is imperative in improving patient care and overall prognosis. Various interventions, such as resistance exercise, nutritional support, and amino acid and vitamin supplementation have shown promise in the management of sarcopenia. However, further insight into novel interventions and indeed, assessment of the benefits of management of sarcopenia in terms of survival, are required to better support cancer patients.